Related posts
Most Anticipated Earnings: SLF-T, REAL-T and more Canadian Companies Reporting Earnings this Week (Nov 13-17)Stocks and gold climbFedEx warning chills marketsThis summary was created by AI, based on 2 opinions in the last 12 months.
The experts' reviews on Aurora Cannabis (ACB-T) indicate a high level of risk and speculation within the sector, particularly with regards to potential catalysts that could drive the stock higher. There is also a consensus that the economics of the cannabis industry are challenging, especially in regions where weed grows easily. The potential for a significant market shift exists if the US were to federalize the legalization of weed, causing a surge in weed-related shares. Overall, the reviews point to a cautious and uncertain outlook for Aurora Cannabis, with a notable lack of confidence in its current valuation.
The problem is that parts of the world weed grows easily, so the economics don't work. The big opportunity will happen when the US legalizes weed federal, then weed shares will pop. If you're under water this, take the tax loss.
Look at what the opportunity is. The US has increased medical and recreational use, plus favourable legislation. Doesn't have the strongest set of assets in the US, so he'd favour MSOs over ACB. Europe is the longer-range opportunity, where it has a foothold.
They each have their own strengths. He would pick Canopy (WEED-T) because they are the 800 lb gorilla. Aurora has lots of news about balance sheet challenges but they have low costs that he thinks will still come down further.
His weed exposure is through Constellation Brands which owns Canopy--this is less risky than owning cannabis stocks. The valuation on the entire sector rose way too high in 2017-8. Now, the industry is feeling growing pains, with unexpected surprises in working with governments. Generally sin stocks do well long term, but the next year or two will be challenging.
Aurora Cannabis is a Canadian stock, trading under the symbol ACB-T on the Toronto Stock Exchange (ACB-CT). It is usually referred to as TSX:ACB or ACB-T
In the last year, 1 stock analyst published opinions about ACB-T. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Aurora Cannabis.
Aurora Cannabis was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Aurora Cannabis.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
1 stock analyst on Stockchase covered Aurora Cannabis In the last year. It is a trending stock that is worth watching.
On 2025-01-10, Aurora Cannabis (ACB-T) stock closed at a price of $5.95.
Avoid the sector. High risk, speculative. Doesn't see catalysts to drive the sector higher, especially if Republicans succeed in the US election.